This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Why OncoMed (OMED) Shares Flew Sky High

NEW YORK (TheStreet) -- Shares of OncoMed Pharmaceuticals (OMED - Get Report) opened sharply higher on news the small-cap biopharmaceutical company was partnering with biotech industry leader Celgene (CELG - Get Report). As part of the agreement, the two companies will develop and co-market up to six anti-cancer stem cell medicines in OncoMed's pipeline.

At Tuesday's open, OncoMed shares were up 77.4% to $23.99.

OncoMed will be responsible for early clinical trials and will retain the rights to co-develop, co-commercialize and share in profits. Celgene has an exclusive option to license demcizumab, OncoMed's most advanced product which is in early-stage trials. OncoMed will be eligible to receive 50% of U.S. profits and royalties for sales internationally if demcizumab makes it to market.

As part of the agreement, OncoMed will receive $177.25 million in an upfront payment from Celgene. Celgene will also purchase $22.25 million of OncoMed's shares, giving it an approximate 5% stake in the company.

"By retaining co-development and co-commercialization rights to up to five biologic product candidates in our pipeline, we expect to add commercial capabilities to our core research and development competencies as we continue to build a premier oncology biotherapeutics company," said OncoMed CEO Paul J. Hastings.

Celgene shares fell 0.95% at market open. The Summit, N.J.-based company is up 107.9% since January.

Must Read: Investors Lose Appetite for Krispy Kreme (KKD)

--Written by Keris Alison Lahiff.

Also see: The 10 Drunkest States in America... and the 10 most sober.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
CELG $103.41 0.00%
OMED $12.40 0.00%
AAPL $93.74 0.00%
FB $117.58 0.00%
GOOG $693.01 0.00%


Chart of I:DJI
DOW 17,773.64 -57.12 -0.32%
S&P 500 2,065.30 -10.51 -0.51%
NASDAQ 4,775.3580 -29.9330 -0.62%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs